However, we did not observe a significant difference of TRH expression in terms of FLT3-ITD mutation, IDH1 mutation, IDH2 mutation, or TP53 mutation in TCGA AML cohort (Figure 3c and Figure S4). This evidence concerns the gene TP53 and acute myeloid leukemia.